Effect of Nephrectomy After Allograft Failure on Inflammation, Erythropoiesis, Donor-Specific Antibodies, and Outcome of Re-Transplantation

12 July 2022 : Original article

Panagiota Zgoura^1BC*, Adrian Doevelaar^1E, Benjamin Rohn^1F, Felix S. Seibert^1CD, Maximilian Seidel^1CD, Falko Markus Heinemann

^2CD, Nina Pillokeit

^3E, Richard Viebahn^3ABCD, Nina Babel^1BCD, Timm H. Westhoff^1ACDE

DOI: 10.12659/AOT.935625

Ann Transplant 2022; 27:e935625

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Study population.

	Transplant in situ (n=49)	Tx-Nephrectomy (n=43)	P
Age (years)	56.3±18.4	54.0±11.3	0.23
Time until transplant failure (months)	125±24	24.5±34.7	<0.001
Live donor transplantation (%)	6 (12.3%)	5 (11.6%)	0.93
CRP (mg/dl)	0.82±0.24	1.12±0.31	0.21
Donor specific antibodies (DSA)	19 (38.8%)	28 (65.1%)
Hb (ml/min)	11.57±0.35	11.83±0.26	0.46
EPO (IE)	6204±1077	4395±1809	0.10
Eisen (mg/Week)	31.46±12.3	47.91±16.45	0.18
Ferritin (ug/l)	387.6±75.12	475.9±88.25	0.25

Dual immunosuppression	18 (36.7%)	0 (0.0%)	0.99
Mono immunosuppression	16 (32.7%)	0 (0.0%)	0.99

Diabetic nephropathy	12 (24.5%)	12 (27.9%)	0.71
Glomerulonephritis	14 (28.6%)	11 (25.6%)	0.74
Hereditary dysplasia/reflux	6 (12.2%)	6 (14.0%)	0.80
Polycystic kidney disease	4 (8.2%)	0 (0.0%)	0.05
Benign nephrosclerosis	2 (4.1%)	2 (4.7%)	0.89
Alport syndrome	3 (6.1%)	0 (0.0%)	0.09
Interstitiell nephritis	1 (2.0%)	2 (4.7%)	0.48
Other causes	7 (14.3%)	10 (23.3%)	0.27
	18 (43.0%)	25 (58.1%)	0.04
	12 (80.0%)	3 (20.0%)	0.11
	1.69±0.83	1.28±0.41	0.08
	46.71±14.0	50.6±8.9	0.36
Numeric data are presented as mean and standard deviation. Numeric data were tested for statistically significant differences using Mann-Whitney-U Test and Fisher’s exact test. P

Back to the Article